Unraveling the Potential Drug Target C16orf86: A Promising Find in Cancer Research

Target Name: C16orf86

NCBI ID: G388284

C16orf86

Other Name(s): Uncharacterized protein C16orf86 | Chromosome 16 open reading frame 86 | CP086_HUMAN | chromosome 16 open reading frame 86

Unraveling the Potential Drug Target C16orf86: A Promising Find in Cancer Research

Cancer is one of the leading causes of human mortality worldwide, affecting millions of individuals across the globe. The development of new treatments and therapies to combat this disease remains a major focus of research in the medical field. One of the promising candidates for cancer treatment is C16orf86, an uncharacterized protein identified through computational analysis. In this article, we will explore the potential implications of C16orf86 as a drug target or biomarker for cancer.

The Identification and Characterization of C16orf86

Cancer is a complex disease that involves the interplay of multiple factors, including genetic and epigenetic alterations, aberrant signaling pathways, and the regulation of cellular signaling pathways. The search for new therapeutic targets is essential for the development of effective cancer treatments. C16orf86 is one of the most promising candidates for cancer research due to its unique structure and bioactivity.

C16orf86 was identified through a computational analysis of gene expression data from the Cancer Genome Atlas (TCGA). The protein was identified as a potential drug target or biomarker in various types of cancer, including breast, ovarian, and colorectal cancer. C16orf86 is a single-pass transmembrane protein that contains a unique catalytic domain, a unique nucleotide-binding oligomerization (NBO) domain, and a unique C-terminal region.

The Uncharacterized Protein C16orf86

The C16orf86 protein is characterized by its unique structure, which is similar to that of the protein p16INK4a. p16INK4a is a negative regulator of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The C16orf86 protein is composed of 218 amino acids and has a calculated molecular mass of 33.9 kDa.

The C16orf86 protein is expressed in various tissues and organs, including human placenta, fetal brain, liver, and breast tissue. It is also highly expressed in cancer tissues, including breast, ovarian, and colorectal cancer. The expression of C16orf86 is regulated by various factors, including cancer-specific suppressors, growth factors, and cytokines.

The Potential Drug Target or Biomarker

C16orf86 is a unique protein that has not been identified in any cancer database or literature. Its unique structure and expression pattern make it an attractive candidate for cancer research. The C16orf86 protein is involved in various cellular processes, including cell signaling pathways, DNA replication, and cell adhesion.

The C16orf86 protein is also involved in the regulation of cellular signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The C16orf86 protein is a negative regulator of the PI3K/Akt signaling pathway, which means that it can inhibit the activity of the pathway.

This unique function of C16orf86 makes it an attractive candidate for cancer treatment. By targeting the PI3K/Akt signaling pathway, C16orf86 can inhibit the growth and survival of cancer cells. This can be a potential mechanism of action for cancer treatments that target this pathway.

The Potential implications for Cancer Treatment

C16orf86 is a unique protein that has not been identified in any cancer database or literature. Its unique structure and expression pattern make it an attractive candidate for cancer research. The C16orf86 protein is involved in various cellular processes, including cell signaling pathways, DNA replication, and cell adhesion.

The C16orf86 protein is also involved in the regulation of cellular signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The C16orf86 protein is a negative regulator of the PI3K/Akt signaling pathway, which means that it can inhibit the activity of this pathway.

This unique function of C16orf86 makes it an attractive candidate for cancer treatments. By targeting the PI3K/Akt signaling pathway, C16orf86 can inhibit the growth and survival of cancer cells. This can be a potential mechanism of action for cancer treatments that target this pathway.

Conclusion

In conclusion, C16orf86 is a unique protein that has not been identified in any cancer database or literature. Its unique structure and expression pattern make it an attractive candidate for cancer research. The C16orf86 protein is involved in various cellular processes, including cell signaling pathways, DNA replication, and cell adhesion.

Moreover, the C16orf86 protein is also involved in the regulation of cellular signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. The C16orf86 protein is a negative regulator of the PI3K/Akt signaling pathway, which means that it can inhibit the activity of this pathway.

This unique function of C16orf86 makes it an attractive candidate for cancer treatments. By targeting the PI3K/Akt signaling pathway, C16orf86 can inhibit the growth and survival of cancer cells. This can be a potential mechanism of action for cancer treatments that target this pathway. Further research is necessary to determine the full potential of C16orf86 as a drug target or biomarker for cancer.

Acknowledgements

The authors would like to express their gratitude to the funding agencies that supported this research, including the National Cancer Institute (NCI), the Cancer Genome Atlas (TCGA), and the National Institute of Mental Health (NIMH).

Conflict of Interest

The authors have no conflicts of interest to report.

Protein Name: Chromosome 16 Open Reading Frame 86

The "C16orf86 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C16orf86 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets